DAX23.766 +0,9%Est505.781 +0,7%MSCI World4.343 -0,1%Top 10 Crypto9,8400 -1,5%Nas22.420 +0,2%Bitcoin64.237 -1,2%Euro1,1528 +0,2%Öl101,8 +0,8%Gold4.988 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Commerzbank CBK100 Siemens Energy ENER6Y Lufthansa 823212 BYD A0M4W9 SAP 716460 Deutsche Telekom 555750 DroneShield A2DMAA Volkswagen (VW) vz. 766403 Bayer BAY001 Allianz 840400 Deutsche Bank 514000 Shell (ex Royal Dutch Shell) A3C99G TUI TUAG50
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX legt zu -- US-Börsen im Plus -- Infineon, STMicro und NXP verkünden Kooperation mit NVIDIA -- DroneShield, Deutsche Bank, Amazon, Sartorius, Rüstungsaktien, Siemens Energy, Microsoft im Fokus
Top News
Nordex bleibt in Breakout-Position aufgrund der hohen Ölpreise! Nordex bleibt in Breakout-Position aufgrund der hohen Ölpreise!
Tesla-Aktie: Neuer Rivale für Optimus - UBTECH Robotics fordert Tesla heraus Tesla-Aktie: Neuer Rivale für Optimus - UBTECH Robotics fordert Tesla heraus
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Eupraxia Pharmaceuticals Aktie

Kaufen
Verkaufen
6,55 EUR +0,40 EUR +6,50 %
STU
7,90 USD +0,49 USD +6,61 %
BTT
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.326,11 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EGRS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCA29842P1053

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolEPRX

Eupraxia Pharmaceuticals Aktien News

DatumMeistgelesen
ZacksWall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet
ZacksEupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy?
ZacksEupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why
ZacksWall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade
PR NewswireEupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces CFO Succession
PR NewswireEupraxia Pharmaceuticals Announces CFO Succession
PR NewswireEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
PR NewswireEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
PR NewswireEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
PR NewswireEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
PR NewswireEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
PR NewswireEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
PR NewswireEupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
PR NewswireEupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
PR NewswireEupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
PR NewswireEupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
PR NewswireLancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
PR NewswireLancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
PR NewswireEupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
PR NewswireEupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
PR NewswireEupraxia Pharmaceuticals Strengthens Senior Management Team
PR NewswireEupraxia Pharmaceuticals Strengthens Senior Management Team
PR NewswireEupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
PR NewswireEupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
PR NewswireEupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireEupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireEupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
PR NewswireEupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

Eupraxia Pharmaceuticals News

Eupraxia Pharmaceuticals News: auf dieser Seite finden Sie alle Eupraxia Pharmaceuticals News und Nachrichten zur Eupraxia Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eupraxia Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eupraxia Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.